StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38+0.00 (0.00%)

Close on Nov 18, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Inhibikase Therapeutics's price to book ratio was 1.4× on Nov 11, 2026, against 1.6× a year earlier. Over the last 5 years it ranged from 0.2× to 3.6×, with a median of 1.2×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.4×−0.7
2025Dec 31, 20252.1×−1.5
2024Oct 31, 20243.6×+3.1
2023Dec 29, 20230.5×−0.0
2022Dec 30, 20220.5×−0.3
2021Dec 31, 20210.8×–

More Inhibikase Therapeutics figures

See a number that looks wrong?